Research programme: human monoclonal antibodies - Centocor/Medarex

Drug Profile

Research programme: human monoclonal antibodies - Centocor/Medarex

Alternative Names: HuMaBs - Centocor/Medarex

Latest Information Update: 03 Sep 2009

Price : $50

At a glance

  • Originator Centocor
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Inflammation; Unspecified

Most Recent Events

  • 02 Sep 2009 Medarex has been acquired by Bristol-Myers Squibb
  • 23 Jul 2008 Medarex files an IND application with the FDA in USA for undisclosed indication
  • 05 Sep 2007 Medarex and Centocor expand their licensing agreement
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top